Dashboard
Manage Tickers

IMMPIMMUTEP Ltd

Nasdaq immutep.com


$ 2.98 $ 0.04 (1.37 %)    

Friday, 17-May-2024 14:51:28 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 451.63 $ -0.22 (-0.05 %)
DIA $ 399.76 $ 0.74 (0.19 %)
SPY $ 529.24 $ 0.76 (0.14 %)
TLT $ 91.40 $ -0.62 (-0.67 %)
GLD $ 223.63 $ 3.63 (1.65 %)
$ 2.96
$ 2.97
$ 0.00 x 0
$ 0.00 x 0
$ 2.97 - $ 3.00
$ 1.58 - $ 3.09
130,512
na
351.44M
$ 0.69
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

capital-one-initiates-coverage-on-immutep-with-overweight-rating-announces-price-target-of-10
Capital One Initiates Coverage On Immutep ...
05/17/2024 15:13:45

Capital One analyst Naureen Quibria initiates coverage on Immutep (NASDAQ:IMMP) with a Overweight rating and announces Price...

earlier-immutep--data-from-safety-lead-in-phase-of-aipac-003-confirmed-complete-response-in-a-patient-with-metastatic-breast-cancer-refractory-to-several-lines-of-therapy-achieved-during-combination-treatment-with-90mg-efti-and-paclitaxel
Earlier: Immutep Data From Safety Lead-in...
05/15/2024 09:17:49

– Immutep Limited ((ASX: IMM, NASDAQ:IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company developing nove...

initial-clinical-data-reported-from-immuteps-efti-combined-with-radiotherapy-and-checkpoint-inhibitor-from-phase-ii-trial-in-soft-tissue-sarcoma
Initial Clinical Data Reported From Immute...
05/02/2024 12:07:35

Novel triple combination of efti with radiotherapy and anti-PD-1 therapy is well tolerated and has led to encouraging initial e...

immutep-reported-cash-cash-equivalent-balance-of-954m-as-of-march-31-2024-giving-it-expected-cash-reach-into-early-cy2026
Immutep Reported Cash, Cash Equivalent Bal...
04/29/2024 09:24:22

12-health-care-stocks-moving-in-wednesdays-intraday-session
12 Health Care Stocks Moving In Wednesday'...
04/24/2024 16:31:39

why-australian-cancer-biotech-firm-immutep-stock-is-soaring-on-wednesday
Why Australian Cancer Biotech Firm Immutep...
04/24/2024 14:43:20

Immutep releases preliminary results from TACTI-003 trial showing promising outcomes for first-line treatment of HNSCC patients...

12-health-care-stocks-moving-in-wednesdays-pre-market-session
12 Health Care Stocks Moving In Wednesday'...
04/24/2024 12:06:37

immutep-announced-tuesday-data--from-efti-in--combination--with-keytruda-in--first--line-head--and--neck--squamous--cell--carcinoma-patients-who-do-not-express-pd-l1-shows-a-preliminary-269-response-rate-the-primary-endpoint-of-the-study
Immutep Announced Tuesday, Data From Efti...
04/24/2024 09:42:00

 Immutep Limited ((ASX: IMM, NASDAQ:IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company developing novel...

immutep-appoints-leading-research-institute-to-conduct-first-in-human-phase-i-study-of-imp761
Immutep Appoints Leading Research Institut...
04/18/2024 12:07:32

Centre for Human Drug Research (CHDR) will conduct Phase I trial to evaluate IMP761, a first-in-class LAG-3 agonist antibody de...

Core News & Articles
Immutep Announced Tuesday, Positive Feedba...
04/17/2024 09:20:38

Immutep Limited ((ASX: IMM, NASDAQ:IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing no...

cancer-focused-immuteps-stock-soars-on-tuesday---heres-why
Cancer Focused Immutep's Stock Soars On Tu...
03/05/2024 20:57:30

Immutep releases promising safety and efficacy data for 90mg eftilagimod alpha combined with paclitaxel in HR+/HER2- metastatic...

immutep-announces-first-clinical-data-from-90mg-dosing-of-efti
Immutep Announces First Clinical Data From...
03/05/2024 13:12:42

Data from the safety lead-in of the AIPAC-003 trial shows 90mg efti in combination with paclitaxel is safe and well toleratedEn...

immutep-q2-2024-cash-and-cash-equivalent-1037m
Immutep Q2 2024 Cash And Cash Equivalent ~...
01/30/2024 13:14:45

first-patient-dosed-in-trial-evaluating-efti-and-the-anti-pd-l1-therapy-bavencio-in-metastatic-urothelial-cancer
First Patient Dosed In Trial Evaluating Ef...
01/04/2024 13:17:06

Immutep Limited ((ASX: IMM, NASDAQ:IMMP) ("Immutep" or "the Company"), a clinical-stage biotechnology company d...

immutep-limited-announces-constructive-feedback-has-been-received-from-the-paul-ehrlich-institut-regarding-the-planned-tacti-004-phase-iii-trial-of-eftilagimod-alpha-for-first-line-treatment-of-metastatic-non-small-cell-lung-cancer
Immutep Limited Announces Constructive Fee...
12/21/2023 13:04:08

Among the other items discussed at the meeting were general aspects of the trial design, including selection of the control arm...

immutep-receives-a26-million-rd-tax-incentive-from-french-government
Immutep Receives A$2.6 Million R&D Tax Inc...
12/07/2023 13:16:33

 Immutep Limited ((ASX: IMM, NASDAQ:IMMP) ("Immutep" or "the Company"), a biotechnology company developing nove...

immutep-secures-a26m-french-rd-tax-incentive
Immutep Secures A$2.6M French R&D Tax Ince...
12/06/2023 21:41:31

immutep-announces-site-expansion-for-insight-003-phase-i-trial
Immutep Announces Site Expansion For INSIG...
11/22/2023 13:03:28

Immutep Limited ((ASX: IMM, NASDAQ:IMMP) ("Immutep" or "the Company"), a clinical-stage biotechnology company d...

immutep-completes-enrollment-in-tacti-003-phase-iib-trial-of-efti-and-keytruda-in-first-line-metastatic-or-recurrent-head-and-neck-squamous-cell-carcinoma
Immutep Completes Enrollment In TACTI-003 ...
11/09/2023 13:02:00

immutep-on-sunday-announced-completion-of-the-safety-lead-in-and-opening-of-the-randomized-phase-ii-of-the-aipac-003-phase-iiiii-trial-in-metastatic-breast-cancer
Immutep On Sunday Announced Completion Of ...
11/06/2023 09:41:49

Immutep Limited ((ASX: IMM, NASDAQ:IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing no...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION